YouTube Insights in 5 Minutes Instead of 3 Hours

• Bitcoin price: Down 3.75% in October so far, but the month isn't over. Year-to-date: BTC -8.1%, SOL -18%, ETH -21.5%, MSTR -5.7%.
• Key levels: Average cost basis of treasury companies at $80,200, spot ETF holders at $81,500. Reclaiming these could provide psychological support.
• Bitcoin’s realized cap is rising – a classic bull market sign and indication that the bear market is over.

• A single wallet bought 800 contracts of $90,000 Bitcoin calls expiring Nov 6 – the largest open Bitcoin options position on the exchange.
• To profit, Bitcoin must rally 12% to above $90,000 by then. Expiry is 3 days after the US midterm elections – buyer may expect positive news.

• Bitcoin ETFs: Net inflow of +$300M last week (after 2 negative weeks), but strong outflows on Thursday/Friday (-$635M in one day) due to AI selloff.
• JP Morgan calls Bitcoin the best long-term asset (expects 10% CAGR, double gold).
• Franklin Templeton suggests allocation to Bitcoin. Germany's Sparkasse launches crypto trading.
• Visa denies acquiring Fireblocks. A16Z sees crypto as key for AI & robotics.

• MicroStrategy (MSTR): No Bitcoin buys last week; buybacks of own stock (STRC) instead. NAV premium at 0.95x.
• Strive: Bought 6,182 BTC for $511M ($82k per BTC) – largest single purchase. Total 43k BTC, now #3 treasury company, soon #2.
• Metaplanet: No buys, NAV premium 0.71x.
• Bitwise (ETH treasury): Holds 4.95% of Ethereum supply (~6.05M ETH). But underwater: cost basis $20.5B, current value $13.9B – unrealized loss of $6.42B.

• Quantum FUD: CASA’s CSO says no immediate threat – years away. If Bitcoin were cracked, all other systems would be compromised first.
• El Salvador offers 0% tax on Bitcoin gains & foreign income after 90 days residency.
• Alchemy possible: Marathon Fusion turns mercury into gold (radioactive, 12-14 years to cool) – Bitcoin remains capped at 21M.
• Shamath (famous Bitcoin critic) again claims Bitcoin will go to zero – commentator warns not to listen to such sentiment makers.

Bottom line: Mixed – short-term bearish signals (ETF outflows, price dip) but bullish long-term indicators (rising realized cap, institutional adoption, big call option). Watch the data, not the emotions.

• Metformin, long popular as an off-label longevity drug, showed a critical downside in active adults: it blunts cardiovascular and muscular adaptations to exercise.
• This drove the search for alternatives that preserve muscle mitochondria – leading to SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin).

• In the Intervention Testing Program (ITP), canagliflozin increased median lifespan by 14% in male mice; female mice saw no benefit.
• In older female mice (starting at 16 months), median lifespan decreased by 6%, possibly due to nearly four times higher drug concentration in the blood.

• Major trials (EMPA-REG, Dapa-HF, DELIVER) with ~18,000 patients show: SGLT2 inhibitors reduce cardiovascular deaths by 38% (in diabetics with CVD) and lower hospitalizations for heart failure – even in patients without diabetes.
• Crucially: All participants had diagnosed heart, kidney, or metabolic disease. No study demonstrates lifespan extension in healthy adults.

• SGLT2 inhibitors block glucose reabsorption in the kidney, causing a daily calorie loss of 160–240 kcal. Blood sugar stays stable because the liver compensates.
• Kidney filters are unloaded (reduced filtration pressure) and heart workload decreases – independent of blood glucose levels.
• Unlike metformin, SGLT2 inhibitors do not impair mitochondrial respiration in muscle, thus not interfering with exercise adaptations.

• Euglycemic ketoacidosis (EU-DKA): Dangerous because blood sugar appears normal while acidic ketones rise. Prevention: no prolonged fasting (>24h: stop drug 48–72h before).
• Infections: Genital fungal infections in ~10–11% of women / ~4% of men. Good hygiene and early treatment are essential.
• Other risks: Increased amputation risk (with canagliflozin), Fournier's gangrene (rare), dehydration from increased fluid loss.
• Contraindications: Type 1 diabetes, advanced kidney disease, low blood pressure.

• SGLT2 inhibitors are not a longevity drug for metabolically healthy people. Data only show benefits in those with existing disease.
• For long-term vitality, exercise (strength and endurance training), balanced nutrition, and quality sleep remain the best foundation.
• Before considering off-label use, have an open discussion with a doctor about your cardiovascular risk, kidney function, and exercise routine.

• Hermès stock has fallen more than 50 % from its peak about 1.5 years ago – even though the underlying business remains solid.
• The question is whether this drop makes it a bargain entry point. The conclusion: No – despite the quality, the stock is not yet cheap.

• Growth: Revenue growth of 6 %; half-year sales are slightly below the post-pandemic boom but show no major weaknesses.
• Earnings: Net profit around €2–2.5 billion; roughly €2 billion excluding exceptional items.
• Balance sheet: Very low debt relative to equity – impressive balance sheet quality.
• Capital allocation: Capital expenditure around 20 % of net profit, with high dividends and capital returns.

• Dividend yield: Only 1.3 % despite the share price decline – too low for a company with medium-to-slow growth prospects.
• P/E ratio: Still around 30 – expensive despite the high quality.
• Market cap: Approximately €140 billion; previously around €280 billion.
• The analyst sees signs of market mania: rising index weights, pension funds and retail investors pushed the stock into bubble territory until a correction occurred.

• Hermès is a top-tier luxury company with a strong brand, scarcity and pricing power.
• But quality alone does not justify an excessive price. Investors are still paying a high premium for safety and prestige – the risk-reward is currently not compelling.

Ross Edgley is a British ultra-endurance athlete who swam around Great Britain (~3,200 km in 157 days), completed a non-stop 510 km swim down the Yukon River, and ran 30 marathons in 30 days. In this conversation with Andrew Huberman, the focus is not on his records but on the psychology and neurobiology of motivation – how to persist through hard things, build resilience, and train your brain for it.

Huberman proposes that motivation is fueled by many different sources – like spokes on a wheel. The key is to flexibly switch between them. Ross confirms: What drives you today may not work tomorrow. Sources he mentions include:

• “Because I said I would” – self-respect and integrity, especially after publicly committing.
• Fear of shame / letting others down – e.g., missing a child’s birth or disappointing the team.
• “F-you energy” – using others’ doubts as fuel (“You’ll never do it”). The more success, the fewer doubts – and the less useful this spoke becomes.
• Love and connection – e.g., the unborn son or a late father. Ross: Thoughts of his dad or son gave him immense strength.
• Gratitude and honoring others – “I can, so I will” – thinking of those who no longer can.
• Money as a legitimate driver – to support family and do more good in the world.
• Joy in the absurd – like Sisyphus: “The struggle alone is enough to fill a man’s heart.”

• Anterior midcingulate cortex (aMCC): This region is linked to tenacity and willpower; it can be strengthened by doing hard things.
• Prefrontal cortex and strategy: The “tube test” shows that activity in prefrontal regions can determine winning vs. losing – independent of hormones or physical strength. The strategy can be love, anger, or ambition.
• Three basic threat options: Move forward, stay still, retreat – also relevant to persistence vs. quitting.

Ross describes how repeated cold exposure and sleep deprivation shift your perception of pain and stress. What once felt unbearable later becomes “normal” – habituation as a training principle. He warns, however, that you need a team to protect you from yourself (“outsourcing common sense”).

• Caffeine & supplements: Ross uses caffeine, alpha-GPC, creatine, etc., deliberately – but emphasizes: first master behavioral basics (sleep, nutrition, training), then use tools.
• Strength training for endurance: A high strength level (e.g., 1RM pull-ups) makes each swim stroke a smaller percentage of your max – reducing injury risk and improving efficiency.
• Mental flexibility: Sometimes “Cyclops mode” (total focus, tunnel vision), sometimes panoramic view and relaxation – depending on context.
• The 2–5 a.m. rule: Don’t trust your thoughts or decisions during those hours.
• Stoicism and storytelling: Ross draws power from myths (Odin, Berserkers, Sisyphus) and personal heroes like his father, who kept coaching tennis from a wheelchair after a terminal cancer diagnosis.

Motivation is not a static resource, but a dynamic system. To achieve great things, you need multiple inner drivers, learn to call on them consciously, and build an environment that carries you – and sometimes stops you. Ultimately, the question is: What story do you tell yourself to keep going?

Summary follows...

Macro analyst Michael Howell discusses whether Bitcoin's recent stability is an early warning that the global liquidity cycle is turning. His base case remains that liquidity bottoms in H2 2027, but Bitcoin holding above $70,000 could signal a shorter and shallower downturn.

• Turbulence → Recession, only government bonds work
• Rebound → Equities and credit, tech leads
• Calm → Equities and commodities, no duration
• Speculation → Commodities, avoid credit, trim equities We are likely at the end of the speculation phase, transitioning toward turbulence.

Rising Treasury yields are not driven by fiscal fears or bond vigilantes. According to Howell, they reflect strong nominal GDP growth and higher rate expectations. Term premia remain low, especially in the US, meaning markets still trust US debt.

• The Fed is deliberately managing bank reserves – they have flatlined recently.
• New tools like RMP are effectively covert QE.
• Treasury Secretary Bessent is pursuing “yield volatility control”: issuing short-dated debt, buying back illiquid off-the-run Treasuries, and dampening bond market volatility.
• This is a form of monetization, but not hyperinflation – likely just 1–2% extra inflation.

Gold is increasingly driven by Chinese PBOC liquidity, not just Western central banks. Howell argues China will be forced to print money, and Chinese demand for gold makes it a key debasement hedge.

• Bitcoin is roughly 5 times more sensitive to global liquidity than gold.
• A 1% change in global liquidity has historically moved the BEST basket (BTC, ETH, SOL) by about 11%.
• As long as Bitcoin stays above $70,000, it may indicate an earlier turning point in liquidity.

• Global liquidity and debt are growing around 8–9% annually, which supports monetary inflation hedges.
• Howell’s advice: “Buy the dips – and buy the bigger dips harder.”
• Gold and Bitcoin should be accumulated on weakness, because the liquidity cycle will eventually turn – the only question is timing.